Cargando…
Why Matter Matters: Fast-Tracking Mycobacterium abscessus Drug Discovery
Unlike Tuberculosis (TB), Mycobacterium abscessus lung disease is a highly drug-resistant bacterial infection with no reliable treatment options. De novo M. abscessus drug discovery is urgently needed but is hampered by the bacterium’s extreme drug resistance profile, leaving the current drug pipeli...
Autores principales: | Ganapathy, Uday S., Dick, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608607/ https://www.ncbi.nlm.nih.gov/pubmed/36296540 http://dx.doi.org/10.3390/molecules27206948 |
Ejemplares similares
-
Epetraborole Is Active against Mycobacterium abscessus
por: Ganapathy, Uday S., et al.
Publicado: (2021) -
TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus
por: Sarathy, Jickky Palmae, et al.
Publicado: (2020) -
In Vitro Profiling of the Synthetic RNA Polymerase Inhibitor MMV688845 against Mycobacterium abscessus
por: Mann, Lea, et al.
Publicado: (2022) -
Extreme Drug Tolerance of Mycobacterium abscessus “Persisters”
por: Yam, Yee-Kuen, et al.
Publicado: (2020) -
A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus
por: Ganapathy, Uday S., et al.
Publicado: (2021)